Impella Versus VA-ECMO for Patients with Cardiogenic Shock: Preliminary Cost-Effectiveness Analysis in the Italian Context
Our analysis suggests that Impella may be cost-saving over VA-ECMO, while also providing better health outcomes for patients with CS; however, discrepancies in costs and reimbursement rates were observed, likely due to variability in patient care and hospital resource utilization. Future real-world studies are needed to confirm these findings, but decision-makers can use this data as an initial reference for health technology assessments in Italy.
Authors
- Rosanna Tarricone (ORCID: https://orcid.org/0000-0002-2009-9357)
- Anna Mara Scandroglio (ORCID: https://orcid.org/0000-0003-0639-8227)
- Vittoria Ardito (ORCID: https://orcid.org/0000-0003-2034-716X)
- Marina Pieri (ORCID: https://orcid.org/0000-0002-4101-800X)
- Carla Rognoni (ORCID: https://orcid.org/0000-0002-6330-0591)
- Dario La Fauci
Institutions
- Vita-Salute San Raffaele University (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- Bocconi University (IT)
Publication Details
- Journal
- Cardiology and Therapy
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1007/s40119-025-00404-w
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.00